The following section provides information on PTC Therapeutics Inc’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into PTC Therapeutics Inc's management and employees, unlock the full data with our company analytics monitoring tool.
Mr. Michael Schmertzler has been the the Chairman of the company's Board since 2004. He has been serving PTC Therapeutics Board since 2001. Mr. Schmertzler served as a Managing Director of Aries Advisors LLC; the sub-advisor to Credit Suisse First Boston Equity Partners LP; and the Chair of the investment committee of Credit Suisse First Boston Equity Partners LP from 2001 to 2015. He served as Co-Head of United States and Canadian Private Equity at Credit Suisse First Boston, an investment banking firm from 1997 to 2001. Prior to 1997, Mr. Schmertzler served in several management roles with Morgan Stanley and its affiliates, including President of Morgan Stanley Leveraged Capital Funds and Head of Morgan Stanley's biotechnology pharmaceuticals group, and was Managing Director and Chief Financial Officer of Lehman Brothers Kuhn Loeb and Head of International Sales and Trading and Investment Banking at its successor, Lehman Brothers. He served as a director of PTC Therapeutics' UK subsidiary until February 2016. Since 2008, Mr. Schmertzler has been an Adjunct Professor and Lecturer at Yale University. He also serves on the Board of Lehman Commercial Paper Inc.
Dr. Stuart W. Peltz has been the Chief Executive Officer and the Director of the company since its inception in 1998. Prior to founding the company, he was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Previously, Dr. Peltz served as a board member of the BioNJ Board of Trustees from 2005 to 2017, including as its Chairman from 2014 to 2016.
Ms. Emily Hill serves as Chief Financial Officer of PTC Therapeutics since June 2019. Prior to this, she served as the company's Senior Vice President and Head of Investor Relations. Ms. Hill also served as the Director of Investor Relations of Warner Chilcott.
Dr. Matthew B. Klein has been the Chief Operating Officer of the company since January 2022. Prior to this, he served as the Chief Development Officer of the company since April 2020. Dr. Klein previously served as the Chief Executive Officer and Chief Medical Officer of BioElectron Technology Corp. Prior to that he served as the Auth-Washington Research Chair of Restorative Burn Surgery at the University of Washington.
Ms. Christine Utter has been the Head of People Services, Senior Vice President and Chief Accounting Officer of PTC Therapeutics since 2019. She previously served as the company's Assistant Controller from 2010 till 2017 and as Principal Financial Officer till 2019. Prior to that, Ms. Utter served as the Assistant Corporate Controller of Barrier Therapeutics and a Financial Analyst at Engelhard Corp.
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer